Related Experiment Videos
TA-CD. Xenova
1Department of Biological Sciences, The Open University, Walton Hall, Milton Keynes, MK7 6AA, UK. moore11@globalnet.co.uk
Idrugs : the Investigational Drugs Journal
|June 12, 2003
Abstract:
TA-CD (formerly IPC-1010), a cocaine conjugate that stimulates the production of antibodies against cocaine, is under development by Xenova (formerly Cantab) for the potential treatment of cocaine dependence [176912], [414867], [449997]. The vaccine was originally discovered at Stanford University and exclusively licensed to ImmuLogic Pharmaceuticals as IPC-1010 [176908]. It was renamed TA-CD when ownership was transferred to Cantab [463510], [463511]. By April 2002, a second phase IIa dose escalation trial was underway [445298], which was ongoing in September 2002 [463866].